Company intelligence / Profile preview

Optimi Health

Vancouver, British Columbia, Canadaoptimihealth.ca ↗

Ownership: Private
Development stage: Commercial

Overview

Optimi Health manufactures GMP-certified MDMA and psilocybin for clinical research and authorized therapeutic use. Their products have been exported to Australia for prescription use by psychiatrists and to New Zealand for a clinical trial. The company has completed large-scale GMP batches of both substances and holds regulatory approvals from Health Canada as well as U.S. FDA drug establishment registration.

Therapeutic areas: Psychiatry
Modalities: Small moleculeNatural product
Industry: Biotech

Drug pipeline

2 assets

psilocybin

Commercial

Indications: Major depressive disorder, Mental health disorders

1 more asset in the full pipeline.

Request access →

Partnerships

Mātai Medical Research Institute/Tū Wairua Project in New ZealandKwantlen Polytechnic University Applied Genomics Centre

Beyond the preview

Go deeper on Optimi Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optimi Health.

Explore the full profile